603087.SH
甘李药业
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 65.47
−4.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.9B | 4.1B | 3.0B | 2.6B | 1.7B |
| Cost of Revenue | 973.4M | 979.0M | 766.5M | 697.4M | 405.8M |
| Gross Profit | 3.0B | 3.1B | 2.3B | 1.9B | 1.3B |
| Operating Expenses | |||||
| R&D Expense | 644.6M | 647.0M | 541.0M | 501.0M | 562.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 256.0M | 268.9M | 255.9M | 216.7M | 247.4M |
| Selling & Marketing Expense | 1.3B | 1.4B | 1.2B | 945.9M | 1.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.2B | 2.2B | 1.9B | 1.6B | 1.8B |
| Cost and Expenses | 3.2B | 3.2B | 2.7B | 2.3B | 2.2B |
| Operating Income (EBIT) | 1.1B | 1.2B | 631.5M | 315.3M | (568.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.1B | 1.2B | 630.4M | 306.1M | (582.5M) |
| Income Tax Expense | 57.9M | 86.2M | 15.7M | (34.1M) | (143.0M) |
| Bottom Line | |||||
| Net Income | 1.0B | 1.1B | 614.7M | 340.1M | (439.5M) |
| Earnings from Cont. Ops | 1.0B | 1.1B | 614.7M | 340.2M | (439.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.0B | 1.1B | 614.7M | 340.1M | (439.5M) |
| Per Share | |||||
| Basic EPS | CN¥1.73 | CN¥1.93 | CN¥1.04 | CN¥0.60 | (CN¥0.78) |
| Diluted EPS | CN¥1.73 | CN¥1.93 | CN¥1.04 | CN¥0.60 | (CN¥0.78) |
| Revenue Per Share | CN¥6.76 | CN¥6.84 | CN¥5.15 | CN¥4.60 | CN¥3.04 |
| Shares | |||||
| Basic Shares Outstanding | 583.3M | 592.5M | 591.0M | 566.8M | 563.5M |
| Diluted Shares Outstanding | 583.3M | 592.5M | 591.0M | 566.8M | 563.5M |
| Profitability Metrics | |||||
| EBITDA | — | 1.5B | 889.3M | 537.8M | (371.3M) |
| D&A | — | 303.8M | 257.8M | 222.5M | 197.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026